In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 101 to 150 of 399

TitleTypeExpected publication date
Digital platforms to support cardiac rehabilitation: early value assessmentHealth technology evaluation
Digital self-help for eating disorders: early value assessmentHealth technology evaluation
Digital technologies delivering CBT for insomnia and insomnia symptoms (provisional title)Health technology evaluationTBC
Digital technologies for managing mild to moderate hip or knee osteoarthritis: early-value assessmentHealth technology evaluation
Digital technologies to support asthma self-management: early value assessmentHealth technology evaluation
Digital technologies to support smoking cessation in secondary care patients: early value assessmentHealth technology evaluationTBC
Domestic violence and abuse: multi-agency workingNICE guidelineTBC
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Technology appraisal guidanceTBC
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]Technology appraisal guidance
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]Technology appraisal guidanceTBC
Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency [ID6415]Technology appraisal guidance
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]Highly specialised technology
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]Technology appraisal guidanceTBC
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID6235Technology appraisal guidanceTBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]Technology appraisal guidanceTBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]Technology appraisal guidance
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]Technology appraisal guidanceTBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]NICE guidelineTBC
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy [ID5073]Technology appraisal guidance
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]Technology appraisal guidanceTBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]Technology appraisal guidanceTBC
Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]Technology appraisal guidance
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317Technology appraisal guidanceTBC
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]Technology appraisal guidanceTBC
Ectopic pregnancy and miscarriage: diagnosis and initial management (update)NICE guidelineTBC
Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy [ID6409]Technology appraisal guidance
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]Technology appraisal guidanceTBC
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]Technology appraisal guidanceTBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]Technology appraisal guidanceTBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]Technology appraisal guidanceTBC
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinomaInterventional procedures guidanceTBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]Technology appraisal guidance
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]Technology appraisal guidanceTBC
Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]Technology appraisal guidanceTBC
Epilepsies in children, young people and adults (extraordinary review)NICE guidelineTBC
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]Technology appraisal guidanceTBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920Technology appraisal guidanceTBC
Ex-situ machine perfusion devices for deceased donor liver transplantsHealth technology evaluation
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology testsDiagnostics guidanceTBC
Familial Breast Cancer: initial assessment and genetic testing (update)NICE guideline
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]Technology appraisal guidanceTBC
Fertility problems: assessment and treatment - update 1 and 2NICE guideline
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]Technology appraisal guidanceTBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Technology appraisal guidanceTBC
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]Technology appraisal guidance
Flow tDCSMedtech innovation briefingsTBC
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]Technology appraisal guidanceTBC
Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]Technology appraisal guidanceTBC
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]Technology appraisal guidance
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic painMedical technologies guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All